Fluorescence In Situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology

Chest

Volumn 138, Issue 1, 2010, Pages 137-144

  Savic, Spasenija ^a   Franco, Noreli ^e   Grilli, Bruno ^a   De Vito Barascud, Audrey ^a   Herzog, Michelle ^a   Bode, Beata ^b   Loosli, Heinz ^c   Spieler, Peter ^d   Schönegg, René ^d   Zlobec, Inti ^a   Clark, Douglas P ^f   Herman, James G ^e   Bubendorf, Lukas ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P14; PROTEIN P15; PROTEIN P16;

ADENOCARCINOMA; ARTICLE; BIOPSY; CHROMOSOME; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE INACTIVATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

EID: 77954481138     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1951     Document Type: Article

References (35)

1. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(suppl 2):ii1-ii19.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591-1603.
3. Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff IJ. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Br J Ind Med. 1988;45(3):182-187. (Pubitemid 18085006)
4. Chapman A, Mulrennan S, Ladd B, Muers MF. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax. 2008;63(5):435-439.
5. Senyiǧit A, Bayram H, Babayiǧit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration. 2000;67(6):615-622. (Pubitemid 32008887)
6. Whitaker D. The cytology of malignant mesothelioma. Cytopathology. 2000;11(3):139-151.
7. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111(1):106-109. (Pubitemid 27043616)
8. Baas P. Optimising survival in malignant mesothelioma. Lung Cancer. 2007;57(suppl 2):S24-S29.
9. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol. 2006;13(6):316-329. (Pubitemid 44673447)
10. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49(6):561-568. (Pubitemid 44924287)
11. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133(8):1317-1331.
12. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24(9):1183-1200.
13. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-2054.
14. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127(2):265-275.
15. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006;170(1):9-15.
16. Shin HJ, Shin DM, Tarco E, Sneige N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer. 2003;99(4):233-239.
17. Tiainen M, Tammilehto L, Mattson K, Knuutila S. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet. 1988;33(2):251-274.
18. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2(3):116-123.
19. Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ. Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol. 2007;35(8):498-502.
20. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23(7):1127-1130.
21. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer. 2002;38(2):131-136.
22. Destro A, Ceresoli GL, Baryshnikova E, et al. Gene methylation in pleural mesothelioma: correlations with clinicopathological features and patient's follow-up. Lung Cancer. 2008;59(3):369-376.
23. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13(4):174-184.
24. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Böcking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114(3):204-215.
25. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51-56. (Pubitemid 36267967)
26. Savic S, Glatz K, Schoenegg R, et al. Multitarget fluorescence in situ hybridization elucidates equivocal lung cytology. Chest. 2006;129(6):1629-1635. (Pubitemid 43894996)
27. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821-9826.
28. Herrmann BG, Frischauf AM. Isolation of genomic DNA. Methods Enzymol. 1987;152:180-183.
29. DeMay RM. Cytology of malignant mesothelioma. In: Pass HI, Volgezang N, Carbone M, eds. Malignant Mesothelioma. New York, NY: Springer; 2005:481-489.
30. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108-2113. (Pubitemid 36687632)
31. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742-747. (Pubitemid 351744840)
32. Flores-Staino C, Darai-Ramqvist E, Dobra K, et al. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer. 2009. [Epub ahead of print].
33. Aggerholm A, Guldberg P, Hokland M, Hokland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 1999;59(2):436-441.
34. Samuels BL, Herndon JE II, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 1998;82(8):1578-1584.
35. Yogelzang NJ, Herndon JE II, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997;79(11):2237-2242.